144 related articles for article (PubMed ID: 30689078)
21. Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy.
Lawania S; Singh N; Behera D; Sharma S
Future Oncol; 2017 Dec; 13(29):2645-2665. PubMed ID: 29035087
[TBL] [Abstract][Full Text] [Related]
22. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
[TBL] [Abstract][Full Text] [Related]
24. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
[TBL] [Abstract][Full Text] [Related]
25. Correlation of CLPTM1L polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.
Liang Y; Thakur A; Gao L; Wang T; Zhang S; Ren H; Meng J; Geng T; Jin T; Chen M
Tumour Biol; 2014 Dec; 35(12):12075-82. PubMed ID: 25155038
[TBL] [Abstract][Full Text] [Related]
26. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
[TBL] [Abstract][Full Text] [Related]
27. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
[TBL] [Abstract][Full Text] [Related]
28. RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.
Chu TQ; Li R; Shao MH; Ye JY; Han BH
Acta Pharmacol Sin; 2016 Nov; 37(11):1490-1498. PubMed ID: 27665847
[TBL] [Abstract][Full Text] [Related]
29. Association of
Walia HK; Singh N; Sharma S
Pharmacogenomics; 2022 Jan; 23(2):97-118. PubMed ID: 34911343
[No Abstract] [Full Text] [Related]
30. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.
Sławińska M; Zabłotna M; Gleń J; Lakomy J; Nowicki RJ; Sobjanek M
Arch Dermatol Res; 2019 Nov; 311(9):697-704. PubMed ID: 31342143
[TBL] [Abstract][Full Text] [Related]
31. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
33. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
34. The role of NQO1 polymorphisms in the susceptibility and chemotherapy response of Chinese NSCLC patients.
Tian G; Wang M; Xu X
Cell Biochem Biophys; 2014 Jul; 69(3):475-9. PubMed ID: 24464627
[TBL] [Abstract][Full Text] [Related]
35. STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer.
Jiang B; Zhu ZZ; Liu F; Yang LJ; Zhang WY; Yuan HH; Wang JG; Hu XH; Huang G
Genet Mol Res; 2011 Aug; 10(3):1856-65. PubMed ID: 21948749
[TBL] [Abstract][Full Text] [Related]
36. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
[TBL] [Abstract][Full Text] [Related]
37. Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients.
Zhang K; Tang S; Cao S; Hu L; Pan Y; Ma H; Guo X; Wu S; Shen H; Hu Z
Cancer Epidemiol; 2014 Aug; 38(4):414-8. PubMed ID: 24797335
[TBL] [Abstract][Full Text] [Related]
38. Association of PSMA4 polymorphisms with lung cancer susceptibility and response to cisplatin-based chemotherapy in a Chinese Han population.
Wang T; Chen T; Thakur A; Liang Y; Gao L; Zhang S; Tian Y; Jin T; Liu JJ; Chen M
Clin Transl Oncol; 2015 Jul; 17(7):564-9. PubMed ID: 25744645
[TBL] [Abstract][Full Text] [Related]
39. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
40. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
